Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced ...
WISH-TV on MSN2h
Lilly to acquire biopharmaceutical company Morphic; aims to improve results for IBD patients
Eli Lilly and Company announced Monday morning that it has reached an agreement to acquire biopharmaceutical company Morphic.
BioSpace6m
Lilly Pays $3.2B to Buy Morphic and Deepen Immunology, Gastro Portfolio
Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in ...
Ibj.com2h
Lilly to buy Massachusetts biopharma company for $3.2B
Massachusetts-based Morphic Holding Inc. is a nine-year old, publicly traded company that is developing a class of drugs known as oral integrin therapies to treat autoimmune diseases, pulmonary ...
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation.
FDA approves new Alzheimer's treatment, donanemab from Eli Lilly
Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the ...
These Stocks Are Moving the Most Today: Tesla, Rivian, Nvidia, Chewy, Lennar, Pure Storage, Eli Lilly, and More
Tesla stock surges after the electric-vehicle maker’s second-quarter deliveries top estimates, and Nvidia shares move lower ...
Eli Lilly history: Beyond the Ticker
With a rich history dating back to the 19th century, Eli Lilly (LLY) has faced struggles and successes. But a booming market ...